PubMed Health⌕ Search

Biomedical subjects

R Van Erum

Publications and source records attributed to R Van Erum.

8 recordsLinked to original sources
PubMed2006

Trans-sinusal maxillary distraction for correction of midfacial hypoplasia: long-term clinical results.

Maxillary distraction osteogenesis is indicated in severe angle class III malocclusions, and severe maxillary hypoplasia among some cleft patients and other craniofacial deformities. Twenty patients, aged 8-48 years (mean 17.8+/-10.5 SD) with maxillary and midfacial hypoplasia were treated. The follow-up period was 13-65 months (mean 35+/-16.3 SD). A trans-sinusal maxillary distractor was placed intraorally at each side of the maxilla. The distraction vector was predicted using specialist software, and was transferred to the patients using stereolithographic models and individual templates. A (high) Le Fort I type osteotomy was performed. The amount of activation varied from 8 to 17.5 mm (mean 13.1+/-2.9 SD). Soft and hard tissue formation resulted in complete healing across the distraction gaps. The distractors are almost completely submerged, and can be left in place as long as necessary to avoid relapse. Wit's appraisal was used to measure the stability of the long-term distraction results. Results up to 5 years after distraction showed considerable maxillary advancement with long-term stability. Ongoing growth of the facial skeleton must be considered when distraction osteogenesis is chosen in growing patients.

Adolescent↗
PubMed2003

Cephalometric evaluation of maxillary advancement with an internal distractor in an adult boxer dog.

OBJECTIVE: The aim of the study was to evaluate cephalometrically the effects of distraction of the maxilla over a 1-year period by means of an internal distractor applied in a boxer dog. DESIGN: Internal distractors were placed bilaterally in the internal cavity of the maxillary sinus of a 2-year-old boxer dog after a Le Fort I osteotomy. Distraction was started 5 days after surgery and activations were continued for 14 days at a rate of 1 mm/day. Standardized lateral cephalograms were taken with an extemal source of 90 kV, 60 mS immediately pre-surgery, at day 1 after the start of the distraction (dp) and at day 5 dp, day 7 dp, day 10 dp, day 14 dp (end of distraction), at 14 days of consolidation period (cp), at 28 days cp and at 56 days cp (removal of the distractors). One year after the removal of the distractor, a final lateral cephalogram was taken. Cephalometric analysis was performed and superimpositions were used for the evaluation of the sagittal position of the maxilla. RESULTS: The linear measurements, as well as the superimposition showed evidence for a significantly advanced position of the maxilla, which was stable 1 year after removal of the distractor. CONCLUSION: The application of the internal maxillary distractor in a boxer dog resulted in a sagittal advancement of the midface that was still present after 1 year.

Animals↗
PubMed2003

Maxillary distraction using a trans-sinusal distractor: technical note.

In this pilot study, the principle of distraction osteogenesis was used to advance the midface of a boxer dog. A modified high Le Fort I-type osteotomy was performed. Following a latency period of 5 days the maxilla was distracted 14 mm in 14 consecutive days at a rate of 1 mm per day. Ten weeks after the completion of the distraction, multiple biopsies were taken across the distraction gap. Histological observation showed bone deposition in the osteotomy sites. Soft and hard tissue formation resulted in complete healing across the distraction gap. The maxillary sinus was used to accommodate the distraction device. Superimposition of the standardized lateral cephalograms taken at the end of distraction and 14 months after the removal of the distractors showed no sign of relapse in the achieved sagittal advancement of the maxilla. This small, intraoral trans-sinusal placed distractor has a completely new conceptual design, and may be helpful in distraction of maxilla in children and adults with midfacial hypoplasia.

Animals↗
PubMed1998

Short stature of prenatal origin: craniofacial growth and dental maturation.

Recently, children born small for gestational age (SGA) with a catch-up growth failure, have been selected for high dose growth hormone (GH) treatment. In order to gain greater insight concerning dentofacial growth and maturation of these patients, and to evaluate the possible effects of high does GH administration on facial structures, craniofacial growth and dental maturation were evaluated in short SGA persons. Seventy-seven cephalograms and orthopantomograms were available from 48 subjects, aged between 2 and 32 years. Craniofacial growth was assessed by calculating age- and gender-specific standard deviation scores (SDS) for eight linear and five angular measurements. Tooth formation was evaluated by means of a dental delay score (i.e. dental age minus chronological age). The SDS for craniofacial growth measurements for the lateral aspect showed a short anterior cranial base (-1.8 SDS), a small retropositioned mandible (< or = -1.7 SDS) and a small maxilla (-1.5 SDS); a high mandibular plane angle (+1.9 SDS) and a wide cranial base angle (+1 SDS). These findings result in a small retrognathic face with a relatively increased lower anterior face height (+1.7 SDS). In contrast to skeletal maturation, dental age was not delayed. The general growth retardation is, apparently, reflected to a differential extent within the craniofacial complex, while dental maturation appears to be a distinct process tightly linked to chronological age, and independent of general growth and bone age.

Adolescent↗
PubMed1998

Craniofacial growth and dental maturation in short children born small for gestational age: effect of growth hormone treatment. Own observations and review of the literature.

Short children born small for gestational age (SGA) may be candidates for treatment with growth hormone (GH). We examined craniofacial growth and dental maturation in a cohort of short SGA children. The general growth failure of these children is reflected to a differential extent within the craniofacial complex. As a group, these children have a small retrognathic face with a relatively increased lower anterior face height; in contrast to skeletal maturation, dental age is not delayed. GH treatment in short prepubertal SGA children leads to craniofacial catch-up growth, which is particularly pronounced in regions where interstitial cartilage is involved, the result being that the facial profile becomes less convex; dental maturation does not appear to be influenced by GH treatment. In conclusion, in short SGA children, GH treatment does not only result in an increase of body stature but also in a trend towards normalization of craniofacial growth and this without notable advancement of dental maturation.

Cephalometry↗
PubMed1994

[The dentofacial complex in hormonal treatment for growth retardation].

The greater availability of growth hormone (GH) and the increasing knowledge of growth hormone physiology have led to a wider application of growth hormone treatment. GH is approved for use in the treatment of pituitary deficiency syndromes and, when properly administered at an early stage, is capable of inducing normal skeletal and muscular development. It has also been successfully used to augment growth in patients with Turner syndrome and the effect on the abnormal craniofacial skeleton of these patients is favourable. The not yet generally approved indications for GH therapy are small children after intrauterine growth retardation, patients with renal insufficiency and patients with osteoporosis. Research is done on effects and possible side-effects into different systems e.g. the craniofacial complex. Dentists and orthodontists who treat growth retarded patients must realize that most of these children have a delay in dentofacial development and in dental maturation and that the facial proportions can be thoroughly different from normal patients. The effect of GH therapy on the craniofacial complex and the dental maturation must also be taken into consideration while planning orthodontic or dental treatment.

Child↗
PubMedDate not supplied

Craniofacial growth in short children born small for gestational age: two years follow-up after high-dose growth hormone treatment.

The craniofacial growth of 17 children born small for gestational age (SGA), who had received high-dose growth hormone (GH) treatment, was studied during the post-treatment phase. The preceding GH treatment consisted of a daily s.c. dose of either 0.2 or 0.3 IU/kg for 2 years. The group consisted of 9 girls and 8 boys with a mean (range) age of 6.9 yr (4-10 years) at the start of the post-treatment period, a mean (SD) bone age of 6.3 (2.1) years, and a mean (SD) height for chronological age of -1.0 (0.6) SDS. During the post-treatment period of 2 years, a catch-down effect was found for all linear craniofacial measurements in both treatment groups, even for the components that had not presented accelerated growth during GH treatment. Major growth vectors, such as the posterior total face height (S-Go) and the overall length of the mandible (Art-Pog), showed a low growth velocity, while minor growth parameters remained almost unchanged during this period. The angular measurements showed no significant changes during this period. It can be concluded that craniofacial growth in short SGA children showed, after a period of GH-induced acceleration, a catch-down period when GH administration is stopped. Despite this low post-treatment growth velocity, the craniofacial linear measurements in lateral aspect, remained larger than in untreated children.

Age Determination by Skeleton↗